Rita Araújo has a degree in Genetics and Biotechnology from the University of Trás-os-Montes and Alto Douro and a Master's in Molecular Oncology from the Institute for Biomedical Sciences Abel Salazar of the University of Oporto and did her thesis work at the Portuguese Institute of Oncology of Oporto (IPO-Porto). After her graduation, she had the opportunity to work as a research fellow at the Centre for CICECO-Aveiro Institute of Materials, at the University of Aveiro, within the FCT project (PTDC/QEQ-MED/1890/2014) which aimed to find metabolic biomarkers of efficacy of a new Palladium-based agent for breast cancer applying NMR spectroscopy. Succeeding her fellowship, she initiated her Ph.D. thesis, inserted in the PTNMR-Doctoral Programme in Nuclear Magnetic Resonance Applied to Chemistry, Materials and Biosciences (PD/00065/2013) where she is studying the oncometabolism of different subtypes of endocrine-breast cancer in different stages of disease progression and evaluating metabolic markers of response to antagonist therapy.
Rita Araújo has a degree in Genetics and Biotechnology from the University of Trás-os-Montes and Alto Douro and a Master's in Molecular Oncology from the Institute for Biomedical Sciences Abel Salazar of the University of Oporto and did her thesis work at the Portuguese Institute of Oncology of Oporto (IPO-Porto). After her graduation, she had the opportunity to work as a research fellow at the Centre for CICECO-Aveiro Institute of Materials, at the University of Aveiro, within the FCT project (PTDC/QEQ-MED/1890/2014) which aimed to find metabolic biomarkers of efficacy of a new Palladium-based agent for breast cancer applying NMR spectroscopy. Succeeding her fellowship, she initiated her Ph.D. thesis, inserted in the PTNMR-Doctoral Programme in Nuclear Magnetic Resonance Applied to Chemistry, Materials and Biosciences (PD/00065/2013) where she is studying the oncometabolism of different subtypes of endocrine-breast cancer in different stages of disease progression and evaluating metabolic markers of response to antagonist therapy.